Presentación de la carrera de Posgrado: Especialización en Diseño Estructural en Obras de Arquitectura

Ponencia presentada den el Congreso CRETA, Santa Fé, 2017Se presenta una nueva carrera de posgrado (N° 11.397/13 CONEAU) entre las Facultadesde Arquitectura y de Ciencias Exactas, Físicas y Naturales, de la Universidad Nacional deCórdoba, con el objeto de aprovechar el potencial académico, científico y tecnológico deambas instituciones.En la Facultad de Arquitectura, se viene insistiendo en la necesidad de articular elconocimiento y la práctica de las diversas disciplinas que confluyen en el proceso de diseño,de modo de generar la conciencia de comprender que el proceso de resolución de laestructura no debe ser separado del diseño del espacio arquitectónico.También, en la carrera de Ingeniería se ha comenzado a revisar el papel del ?ingenierocalculista? intentando abrir el espectro en la formación disciplinar hacia el diseño de laestructura. Esta idea se ve fortalecida por el enfoque de las reglamentaciones yrecomendaciones contenidas en los Nuevos Reglamentos CIRSOC en los cuales se haceénfasis en el ?DISEÑO ESTRUCTURAL?, expresión que resulta más abarcativa queCalculo Estructural.Es por ello que el Profesor Arquitecto Hugo Bonaiutti, convocó a un equipo de docentes deArquitectura e Ingeniería Civil para trabajar en una propuesta académica de posgrado sobrediseño estructural en obras de arquitectura, destinada especialmente a egresados de ambascarreras.En este contexto, la carrera de especialización creada, tiene el objetivo de formarprofesionales arquitectos e ingenieros con habilidades y conocimiento específico en elDiseño de Estructuras, articulando los aspectos derivados del cálculo, dimensionado yanálisis estructural con el diseño arquitectónico, considerado de manera integral.http://www.fadu.unl.edu.ar/congresocreta2017/docs/ix-creta_libro-de-ponencias.pdfFil: Simonetti, Isolda. Universidad Nacional de Córdoba. Facultad de Arquitectura, Urbanismo y Diseño; ArgentinaFil: Fernández Saiz, María del Carmen. Universidad Nacional de Córdoba. Facultad de Arquitectura, Urbanismo y Diseño; ArgentinaFil: Fabre, Raquel. Universidad Nacional de Córdoba. Facultad de Arquitectura, Urbanismo y Diseño; ArgentinaFil: Culasso, María Gabriela. Universidad Nacional de Córdoba. Facultad de Arquitectura, Urbanismo y Diseño; ArgentinaFil: González, Gustavo. Universidad Nacional de Córdoba. Facultad de Arquitectura, Urbanismo y Diseño; ArgentinaOtras Ingenierías y Tecnología

patrimonio intelectual

Actas de congresoLas VI Jornadas se realizaron con la exposición de ponencias que se incluyeron en cuatro ejes temáticos, que se desarrollaron de modo sucesivo para facilitar la asistencia, el intercambio y el debate, distribuidos en tres jornadas. Los ejes temáticos abordados fueron: 1. La enseñanza como proyecto de investigación. Recursos de enseñanza-aprendizaje como mejoras de la calidad educativa. 2. La experimentación como proyecto de investigación. Del ensayo a la aplicabilidad territorial, urbana, arquitectónica y de diseño industrial. 3. Tiempo y espacio como proyecto de investigación. Sentido, destino y usos del patrimonio construido y simbólico. 4. Idea constructiva, formulación y ejecución como proyecto de investigación. Búsqueda y elaboración de resultados que conforman los proyectos de la arquitectura y el diseño

Projeto Ministério Público Social: a participação como estratégia para a materialização dos direitos (Social Public Ministry Project: participation as a strategy for the realization of rights)

This article addresses the category “social participation” used as a strategy for the materialization of rights, through the Strategic Project “Public Social Ministry” of the State of Paraná. The main objective was toidentify the importance of population participation in the execution of social control mechanisms. We start from the assumption that it is essential the existence, interlocution and good functioning of the participation instances as a fundamental element in guaranteeing the social and political rights of the population. Thus, through the bibliographical review, we constructed an argumentative basis based on some theoretical categories such as: history of the democratic State of rights and the conception of social participationthat enabled us to base the qualitative analyzes of the data collected. Participants were members and servants of the Public Ministry of Paraná and representatives of the Pontifical Catholic University of Paraná, partner institution in the development of actions. Among the many indicators and results obtained, we note the importance of qualified and critical social participation of the population, as a means of guaranteeing social, political and human rights, which result from the recognition of historical achievements arising from struggles and popular organization.Este artigo aborda a categoria “participação social” utilizada como estratégia para a materialização de direitos, por meio do Projeto Estratégico “Ministério Público Social” do Estado do Paraná. O objetivo principal foi de identificar a importância da participação da população na execução de mecanismos de controle social. Parte-se do pressuposto que é imprescindível a existência, interlocução e bom funcionamento das instâncias de participação como elemento fundamental na garantia de direitos sociais e políticos da população. Deste modo, por meio, da revisão bibliográfica foi construída uma base argumentativa a partir de algumas categorias teóricas tais como: histórico do Estado democrático de direitos e a conceituação de participaçãosocial que possibilitou fundamentar as análises qualitativas dos dados coletados. Foram envolvidos na pesquisa: membros e servidores do Ministério Público do Paraná e representantes da Pontifícia Universidade Católica do Paraná, instituição parceira no desenvolvimento das ações. Dentre os diversos indicadores e resultados obtidos, foi constatada a importância da participação social qualificada e crítica da população, como um meio de garantia dos direitos sociais, políticos e humanos, que resultam no reconhecimento das conquistas históricas advindas das lutas e da organização popular

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis

With the advent of more effective therapy for the bone marrow in acute promyelocytic leukemia (APL) central nervous system (CNS) prophylaxis has been suggested to be useful. Using data from 739 patients treated on two Spanish national trials, the authors examine the incidence of CNS relapse in APL and whether risk factors for such relapse can be identified

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

PETHEMA, HOVON, PALG, GATLA cooperative groups.[Objective] The obesity/overweight may have an influence on APL outcomes.[Methods] This is the biggest multicentre analysis on 1320 APL patients treated with AIDA‐induction and risk‐adapted consolidation between 1996 and 2012. Patients body mass index (BMI) was classified as underweight (<18.5 kg/m2), normal (18.5‐25 kg/m2), overweight (25‐29.9 kg/m2), and obese (≥30 kg/m2) according to the World Health Organization (WHO) criteria.[Results and conclusions] Relationship between male gender, older age, and other known laboratory abnormalities in overweight/obese patients was significant. The induction mortality rate was significantly higher in APL with BMI ≥25 vs BMI <25 (10% vs 6%; P = .04). APL patients with BMI ≥25 had a trend to lower OS (74% vs 80%; P = .06). However, in the multivariate analysis, BMI did not retain the independent predictive value (P = .46). There was no higher incidence of differentiation syndrome with BMI ≥25, but there was a trend in obese. There was no difference in relapse rate according to the BMI. In summary, overweight/obesity does not represent an independent risk factor for APL outcomes. The influence of obesity in APL patients treated with chemotherapy‐free regimens remains to be established.This work was partially financed with FEDER funds (CIBERONC (CB16/12/00284)) and with Instituto de Investigación Sanitaria La Fe funds (2014/0368)

PLZF-RARα, NPM1-RARα, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

It has been suggested that 1&ndash;2% of acute promyelocytic leukemia (APL) patients present variant rearrangements of retinoic acid receptor alpha (RAR&alpha;) fusion gene, with the promyelocytic leukaemia zinc finger (PLZF)/RAR&alpha; being the most frequent. Resistance to all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested in PLZF/RAR&alpha; and other variant APLs. Herein, we analyze the incidence, characteristics, and outcomes of variant APLs reported to the multinational PETHEMA (Programa para el Tratamiento de Hemopatias Malignas) registry, and we perform a systematic review in order to shed light on strategies to improve management of these extremely rare diseases. Of 2895 patients with genetically confirmed APL in the PETHEMA registry, 11 had variant APL (0.4%) (9 PLZF-RAR&alpha; and 2 NPM1-RAR&alpha;), 9 were men, with median age of 44.6 years (3 months to 76 years), median leucocytes (WBC) 16.8 &times; 109/L, and frequent coagulopathy. Eight patients were treated with ATRA plus chemotherapy-based regimens, and 3 with chemotherapy-based. As compared to previous reports, complete remission and survival was slightly better in our cohort, with 73% complete remission (CR) and 73% survival despite a high relapse rate (43%). After analyzing our series and performing a comprehensive and critical review of the literature, strong recommendations on appropriate management of variant APL are not possible due to the low number and heterogeneity of patients reported so far

PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial

The role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography (PET) has not been established in classical Hodgkin lymphoma (cHL). Patients with stage I–IV cHL, received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan (PET3). PET3-negative patients received no further therapy. PET3-positive patients received three additional cycles of ABVD plus involved-field radiation therapy or salvage chemotherapy, if refractory to ABVD, and were re-evaluated by PET scan (PET6). Study endpoints were 3-year progression-free survival (PFS) and overall survival (OS) rates. Two hundred and thirty-nine patients with early-stage and 138 with advanced-stage were evaluable. Overall, 260 patients (70%) were PET3-negative and had higher 3-year PFS (90% vs. 65%; P < 0 0001) and OS (98% vs. 92%; P = 0 007) rates than PET3-positive patients. All PET3-negative patients, regardless of disease stage at diagnosis, achieved similarly good PFS (90–91%; P = 0 76) and OS (97–99%). The only independent prognostic factor for PFS was PET3-negativity (Hazard ratio 3 8; 95% confidence interval 2 4–6 3; P < 0 0001). This study suggests that cHL patients who achieve a negative PET3 following ABVD have an excellent outcome, regardless of stage at diagnosis. An appropriately powered, phase III trial will be necessary to confirm these findings.Fil: Pavlovsky, Astrid. Fundación Para Combatir la Leucemia; Argentina. Centro de Hematología Pavlovsky; ArgentinaFil: Fernández, Isolda. Fundación Para Combatir la Leucemia; Argentina. Centro de Hematología Pavlovsky; ArgentinaFil: Kurgansky, Nicolas. Doctus; ArgentinaFil: Prates, Virginia. Hospital Italiano de La Plata; ArgentinaFil: Zoppegno, Lucia. Hospital General San Martín; ArgentinaFil: Negri, Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Privado de Hematología y Hemoterapia; ArgentinaFil: Milone, Gustavo. Fundación Para Combatir la Leucemia; ArgentinaFil: Cerutti, Ider. Idhea Clinica Hematologica Dr Cerutti Ider; ArgentinaFil: Zabaljauregui, Soledad. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: Mariano, Romina. Provincia de Entre Rios. Hospital San Martin; ArgentinaFil: Grecco, Horacio F.. Sanatorio Dr. Julio Méndez; ArgentinaFil: Basquiera, Ana Lisa. Hospital Privado Universitario de Cordoba.; ArgentinaFil: Saba, Silvia. Hospital Rodolfo Rossi; ArgentinaFil: Rudoy, Silvia. Clínica Modelo de Morón; ArgentinaFil: Sackmann, Federico. Fundación Para Combatir la Leucemia; ArgentinaFil: Castano, Vanesa. Idhea Clinica Hematologica Dr Cerutti Ider; ArgentinaFil: Remaggi, Guillermina. Fundación Para Combatir la Leucemia; ArgentinaFil: Cabrejo, María del Rosario. Sanatorio Dr. Julio Méndez; ArgentinaFil: Roveri, Eriberto. Idhea Clinica Hematologica Dr Cerutti Ider; ArgentinaFil: Casale, María Florencia. Instituto Privado de Hematología y Hemoterapia; Argentina. Hospital General Centeno; ArgentinaFil: Cabane, Vanina. Clínica Dr. Roberto Raña; ArgentinaFil: Taus, Rossana. Hospital Rodolfo Rossi; ArgentinaFil: Venturini, Claudia. Instituto Privado de Hematología y Hemoterapia; ArgentinaFil: Sakamoto, Francisco. Instituto Privado de Hematología y Hemoterapia; ArgentinaFil: Varela, Ana I.. Sanatorio Las Lomas Sociedad Anonima.; ArgentinaFil: Riddick, Maximiliano Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Departamento de Matemáticas; ArgentinaFil: Pavlovsky, Santiago. Fundación Para Combatir la Leucemia; Argentin

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with <2 ACA (p=.09). Among patients with CK+, the 5-year CIR was 27% vs 12% (p=.003), retaining the statistical significance in multivariate analysis. This study shows an increased risk of relapse among APL patients with CK + treated with ATRA plus chemotherapy front-line regimens